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Severe snakebites in northern KwaZulu-Natal: Treatment 
modalities and outcomes
Darryl Wood, Caroline Webb, Jenine DeMeyer
Snakebites are common in the sub-tropical north-eastern 
region of KwaZulu-Natal. Several studies have investigated 
the epidemiology of snakebites in hospitals in rural Kwazulu-
Natal.1-3 We aimed to observe outcomes of severe snakebites in 
patients admitted to Ngwelezana Hospital. Seasonal variations 
of snakebites and the effectiveness and complications of 
antivenom were assessed.
KwaZulu-Natal and Mpumulanga have the highest 
incidences of snakebites in South Africa, with 24 - 34 per 100 
000 people being bitten annually.4 Less than 10% of snakes in 
southern Africa are potentially lethal; the reported snakebite 
mortality rate is 1 - 2%.4 The snakes responsible for severe bites 
in the study region include: forest cobra (Naja melanoleuca), 
M’Fezi or Mozambique spitting cobra (Naja mossambica), 
Egyptian cobra (Naja haje), black mamba (Dendroaspis 
polylepis), green mamba (Dendroaspis angusticeps), boomslang 
(Dispholidus typus), vine snake (Thelotornis capensis), puff adder 
(Bitis Arietans) and Gaboon viper (Bitis gabonica).2 The most 
commonly reported dangerous snakebites are from the M’fezi 
and puff adder,2 while the notorious black mamba causes life-
threatening neurotoxic envenomation.
Empangeni is a town in north-eastern KwaZulu-Natal. 
Ngwelezana Hospital is a 500-bed hospital situated in a semi-
rural settlement outside Empangeni, and is the referral centre 
for 22 rural hospitals. It has an emergency medicine unit 
(EMU) where all snakebite patients are observed and treated.
Antivenom is manufactured by the South African Institute 
for Medical Research (SAIMR).5 It neutralises active snake 
venom and is the definitive management for severe snakebite 
envenomation. Polyvalent antivenom is effective against most 
snakes that are likely to cause life-threatening envenomation 
in southern Africa, except certain adders, the boomslang and 
the vine snake. The SAIMR has produced two monovalent 
antivenoms for the haemotoxic boomslang and the saw-scaled 
viper.
The indications for antivenom use are listed in Fig. 1. Studies 
in Eshowe and Durban showed that up to 41 - 50% of patients 
experienced an adverse effect to antivenom use.1,6 Acute 
anaphylaxis (e.g. hypotension, bronchospasm) is not dose-
related and typically occurs 1 - 15 minutes after antivenom 
administration.5 Milder allergic reactions such as urticaria and 
tachycardia can also be experienced. Serum sickness (urticaria, 
polyarthritis, mild fever and lymphadenopathy) is usually 
delayed by up to 7 - 12 days.5,7 Test dosing with antivenom 
is no longer recommended.8 Fig. 2 shows the guidelines for 
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Objective. We aimed to study the outcomes of severe 
snakebites in patients admitted to Ngwelezana Hospital in 
north-eastern KwaZulu-Natal, the seasonal variations, and the 
effectiveness and complications of antivenom.
Design. A prospective observational outcomes study was 
conducted over one year (1 June 2007 to 31 May 2008). The 
study group was from the north-eastern KwaZulu-Natal 
region of South Africa, with a population of approximately 
3 million people, and included all patients bitten by snakes 
and admitted to the Ngwelezana Hospital Emergency 
Medicine Unit (EMU). Departmental practice guidelines were 
documented and followed.
Outcome measures. End-points for patient outcomes included 
transfer from the EMU to the ward, discharge home from the 
EMU, and follow-up of patients who required surgery or ICU 
care.
Results. A total of 243 snakebite patients were recorded. The 
highest incidence was in the summer months; 46 (18.93%) 
patients experienced one or more severe complications; 
29 (11.93%) patients received some form of definitive 
management in hospital; and 22 (9.05%) of the latter patients 
received antivenom. Antivenom was administered to more 
children than adults. Adverse reactions to antivenom were 
common: an allergic response occurred in 4 (15.4%) patients, 
and anaphylaxis in 6 (23.1%); the highest incidence occurred 
in the <10-year-old age group. No deaths were recorded.
Conclusions. Snakebites are common in the summer months 
in north eastern KwaZulu-Natal. Children are particularly 
vulnerable to snakebites and the effects of antivenom. 
Adverse reactions to antivenom are common. Severe 
snakebites that require antivenom should be managed 
in a hospital setting with advanced airway support. The 
syndromic approach to treatment is simple and effective.
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administering antivenom. The effectiveness of premedication 
with hydrocortisone, antihistamines and intramuscular 
adrenaline in reducing the risk of anaphylaxis is unknown.8
The dose of antivenom depends on the type and amount of 
venom injected rather than the weight of the patient. Children 
therefore receive the same amount of antivenom as adults. 
Further doses can be given and are titrated against the patient’s 
response. Haemotoxic venoms tend to have a delayed onset.2
Practice guidelines adapted from Blaylock were used in this 
study.8
Methods
A prospective observational outcomes study from north-
eastern KwaZulu-Natal, with a population of approximately 
3 million people, was conducted over 1 year (1 June 2007 to 
31 May 2008). All patients who were bitten by snakes and 
admitted to the Ngwelezana Hospital EMU were documented. 
Departmental practice guidelines were followed (Fig. 1). All 
snakebite patients from the immediate local area (Uthungulu) 
were included. Only those with severe symptoms from 
outlying referral hospitals were accepted for admission to the 
EMU.
The data were collated daily by two doctors working in the 
EMU. Endpoints for patient outcomes were:
•   transfer from the EMU to the ward
•   discharge home from the EMU
•    follow-up and documentation of patient outcomes with 
severe progressive symptoms requiring surgery or ICU care.
All patients with suspected snakebites admitted to the EMU 
were included and confirmed by cross-reference with the 
admission logbook of the unit.
Every patient was reviewed by a senior doctor (principal 
medical officer, chief medical officer or consultant) within 
12 hours of admission. The management guidelines classify 
envenomation symptoms as painful progressive swelling, 
progressive weakness and bleeding.8 Patients with severe 
symptoms were observed for at least 12 hours, with regular 
documentation of the progression of swelling, neurological 
status, signs of bleeding and examination for compartment 
syndrome. Patients with an uneventful course were transferred 
to the ward. Patients with unconvincing snakebite symptoms 
(absence of fang marks or no local swelling) were discharged 
home following a period of observation and normal blood 
results. The causative snake was rarely identified as patients’ 
herpetological knowledge was generally unreliable, and 
invariably the snake was not seen at the time of the bite.2
Severe complications associated with snakebites were 
categorised according to specific criteria:
1.    Rapid progressive swelling. Swelling crossing 2 large 
joints within 4 hours or the entire limb by 8 hours following 
the snakebite. Snakebites that potentially compromised the 
airway were also included in this category.
2.    Compartment syndrome. Following rapid progressive 
swelling, an increase in compartmental pressure resulting 
in microcirculatory arrest and vascular compromise to 
the limb.6 Snakebites usually cause subcutaneous oedema 
without raised compartment pressures.8 We did not 
measure compartmental pressures.
3.    Haematological disorder. An international normalised 
ratio (INR) >1.5, haemoglobin <8.0 g/dl or platelet count 
<50×109/l.
4.    Neurotoxicity. Symptoms suggestive of neurotoxicity from 
envenomation typically include drowsiness or a depressed 
level of consciousness, limb weakness, sweating, vomiting, 
inability to swallow saliva, ptosis, blurred or double vision, 
and respiratory muscle paralysis.4
Fig. 1. Guidelines for the management of snakebites.
*Boomslang monospecific 10 - 20 ml for boomslang/vine snake; polyvalent 50 ml for puff adder;
polyvalent 200 ml for Gaboon viper.
Adapted from Blaylock.8
• Re-assess at 1 h
Swelling bite site spreading proximally
Painful adenopathy
Blisters ± necrosis
(debride after 5 - 7
days)
Swelling to knee/elbow in 4 h
Swelling of whole limb in 8 h
Compartment syndrome – rare
Coagulation disorder – exclude
ELEVATE LIMB
Treat coagulopathy if present (FFP/FDP)
Antivenom polyvalent* 40 ml IVI
Mannitol (0.5 - 1 g/kg)
• No response to elevated limb after 1 h
or
• Low/dropping platelet levels (<50)
Open full length fasciotomy
Compartment pressure high (>30
mmHg)
No coagulopathy
1. Painful progressive swelling
Snakes = puff adder, spitting cobra, stiletto
snake, night adder, Gaboon viper
2. Progressive weakness
Triad: pins/needles, sweating+++, salivation+++,
(metallic state)
Life-threatening envenomation
• Weakness and SOB
• Unable to swallow saliva
• Ptosis and dilated pupils
• Respiratory distress
A. Intubate if airway compromised
B. Ventilate if required
C. Fluids
D. Antivenom polyvalent * 80 - 100 ml
E. ICU
Snakes = cobras e.g. rinkhals (tender bite site), mamba
(non-tender bite site), berg adder
Fang punctures do not stop bleeding
Headache, fainting or convulsions
• Active systemic bleeding
• Blood placed in test tube does not
clot after 20 minutes
• INR; PI/PTT deranged
• Antivenom* polyvalent
Snakes = boomslang, vine snake – specific
haemotoxins; puff adder and Gaboon viper – cyto +
haemotoxic
3. Bleeding
Fig. 1. Guidelines for the management of snakebites.
Fig. 2. Antivenom administration.
1. Severe life- or limb-threatening envenomation
2. Discuss with emergency medicine or surgical consultant before administering antivenom
3. Doctor with airway skills needed to assist (senior EMU doctor or anaesthetist)
4. Facemask oxygen; two large-bore cannulas (>18 G) with normal saline running
5. Monitor blood pressure, pulse and saturation
6. Resuscitation trolley and defibrillator on standby
7. Premedication: 1. IVI hydrocortisone 200 mg in adults; 4mg/kg in children at least 30 minutes prior to antivenom
2. IVI phenergan 25 - 50 mg diluted in 10 × water in adults ; IMI (0.125 - 0.5 mg/kg) in children >5
years may be considered; avoid in children <5 years.
3. IMI adrenaline 0.3 - 0.5mg in adults; 0.05 - 0.1 ml/kg in children
8. 40 ml antivenom IV over 15 minutes (test dose not required)
*Repeat doses (1 - 4 vials) may be required every 1 - 2 hours if symptoms persist; larger doses may be required (up to 100 ml) in
neurotoxic envenomation.
Fig. 2. Antivenom administration.
1mg in adults; 0.01 mg/kg i  il ren
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Snakebites are usually categorised according to the 
primary action of their venom into cytotoxic, haemotoxic and 
neurotoxic. However, many snakes inject a variety of toxic 
compounds that may cause more than one type of syndrome.6 
Patients with more than one type of severe complication had 
each one documented separately.
Antivenom administration was at the discretion of the 
consultant, according to departmental guidelines (Fig. 2). 
In all cases resuscitation equipment was on standby, in 
readiness for anaphylaxis. Hydrocortisone, antihistamine 
and adrenaline were given prior to the antivenom. The 
SAIMR polyvalent antivenom was diluted in saline and 
administered over a 15-minute period, with careful monitoring 
for allergic or anaphylactic responses.5 An initial standard 
dose of 4 vials of antivenom was used, regardless of age, and 
repeated as necessary. Patients with neurotoxic snakebites 
typically required higher doses of antivenom; endotracheal 
intubation was considered in these cases owing to the risk of 
respiratory muscle paralysis. Adverse reactions to antivenom 
administration were classified as either allergic (mild response, 
most commonly manifested as pruritus, skin weals and an 
associated tachycardia) or anaphylactic (severe, potentially 
life-threatening systemic reaction). Patients who became 
hypotensive or experienced bronchospasm were classified as 
having an anaphylactic reaction. Only acute reactions were 
documented. Serum sickness was not investigated owing to the 
inability to follow up patients after discharge from the EMU.
Results
A total of 243 snakebite patients were recorded; 29 (11.93%) 
were referred from peripheral hospitals within the Ngwelezana 
catchment area. Most snakebites were recorded in January (Fig. 
3) (peak of summer, with average daily temperatures of around 
32ºC and high humidity levels). The data show a rising trend in 
snakebites in the summer months. The most common snakebite 
population groups were children and young adults; 137 (56.4%) 
were <20 years old (Fig. 4).
Most patients (81.1%) had mild symptoms. One or more 
severe snakebite complications were experienced by 46 (18.9%), 
as follows: haemotoxicity in 27 (58.7%); rapid progressive 
swelling in 18 (39.1%); compartment syndrome was diagnosed 
clinically in 4 (8.7%), but only one patient received a 
fasciotomy; and neurotoxicity in 3 (6.5%). All of them received 
antivenom. No patients died.
Twenty-nine (11.9%) patients received some form of 
definitive management; some received more than one, 
depending on complexity of the symptoms. Antivenom was 
administered to 75.9% of all patients who required definitive 
treatment; 22 (9.1%) received antivenom. Blood products 
(packed red cells, fresh-frozen plasma or platelets) were given 
in 6 cases; 3 required endotracheal intubation in the EMU (2 for 
severe neurotoxicity and 1 for anaphylaxis due to antivenom 
administration); and 11 (4.5%) required surgery including 
debridement of necrotic snakebite wounds, amputation of 
affected limbs or digits, or fasciotomy. All 4 cases of clinically 
diagnosed compartment syndrome received antivenom. One 
patient required a fasciotomy.
Antivenom administration
Twenty-two patients were given antivenom; 4 received 
antivenom at their referral hospitals before admission to the 
Ngwelezana EMU. Half of the patients given antivenom at 
Ngwelezana came from referring hospitals. Only patients 
with complicated snakebites that could not be managed at 
the peripheral referring hospitals were sent to Ngwelezana 
Hospital for further treatment.
Antivenom was administered to more children than adults: 
15 (68.2%) patients receiving antivenom were <20 years old (0 
- 10 years: 8, 11 - 20 years: 7, ≥20 years: 7). The most common 
indication for antivenom administration was rapid progressive 
swelling (14 (46.7%) of patients), with haemotoxicity in 8 
(26.7%) coming next. All 4 cases of clinical compartment 
syndrome received antivenom. One patient received antivenom 
for venom-related shock. Many patients met the criteria for 
more than one indication for antivenom administration.
The mean time to antivenom administration was 16 hours 
after the bite; this delay can be attributed to:
Fig. 3. Monthly distribution of snakebite patients.
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Fig. 4. Age distribution of snakebite patients.
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•   lack of transport in rural areas
•   transfer of patients from referring hospitals
•    patients seeking advice from traditional healers before 
going to hospital
•    prolonged observation of symptom progression in the EMU.
Adverse reactions to antivenom were common; only 7 
(31.8%) patients received antivenom without any adverse 
reaction. An allergic response occurred in 4 (15.4%) cases 
and anaphylaxis in 6 (23.1%) (Table I). Two patients were 
transferred to the ICU: an adult male with neurotoxic snakebite 
symptoms, and a young girl with rapid progressive swelling, 
compartment syndrome and reperfusion injury. One patient 
was transferred to a tertiary hospital following an anaphylactic 
reaction to the antivenom.
The highest percentage of adverse reactions to antivenom 
occurred in the 0 - 10-year age group, while most adults 
(85.7%) experienced no complications (Table I). Of the 8 
patients under the age of 10 who received antivenom, only 
2 (25%) had no adverse reaction. The highest proportion of 
anaphylactic reactions occurred in the 11 - 20-year age group 
(42.9%).
Discussion
Snakebites are common in KwaZulu-Natal. A study at a 
similar hospital in this region reported 282 severe bites over 
a 32-month period.1 As with similar studies in the region, the 
highest seasonal incidence was during the warm summer 
months.1,2
The EMU guidelines are based on those of Blaylock.8 These 
follow a syndromic approach, which classifies the clinical 
presentation of the patient, the severity of the bite and 
appropriate treatment, including antivenom. This approach 
negates the need to identify the species of snake, focuses on 
managing the presenting signs and symptoms, and is very 
effective for early and appropriate management of snakebites. 
Despite the high number of patients who were admitted to the 
EMU, most did not have severe complications (81%). However, 
46 (19%) developed severe complications that required 
intensive monitoring and treatment. There was no mortality 
during the study period using these guidelines.
Most patients who develop severe complications need 
some form of active medical intervention. The most common 
complication from snakebites was haemotoxicity (59%), usually 
involving a thrombocytopenia which, when significant (defined 
as platelets <50×109/l), required antivenom administration. The 
mechanism of acute thrombocytopenia is not fully understood, 
but antivenom reverses the effect rapidly and is preferred to 
platelet replacement. Rapid progressive swelling (RPS) was 
seen in 39% of patients with complications. The incidence of 
clinical compartment syndrome in snakebites is low (9% in the 
selected patient population with RPS), probably as most snake 
fangs penetrate the subcutaneous tissue rather than the muscle 
fascial compartment. However, RPS should be monitored 
closely as it can potentially cause significant morbidity. One 
of our patients required a fasciotomy and 3 needed limb 
amputations.
The use of antibiotics in RPS with blistering/bullae is not 
recommended in the acute setting. The snake’s mouth and bite 
have very few micro-organisms, and venom has antibacterial 
properties.1 When infection occurs, the organisms responsible 
are usually Gram-negative enterobacteriaceae. Gas gangrene 
and tetanus have not been described in southern African 
snakebite research.
Children appear to be most vulnerable to snakebites. In our 
study, the highest incidence of snakebite was in the <20 years 
age group. Children’s natural curiosity and the fact that young 
boys are used as herders in rural farming areas have been 
cited as a further risk for snakebites.6 There is also evidence 
that children are at higher risk for severe symptoms such as 
swelling, compartment syndrome and neurotoxic respiratory 
compromise; Blaylock suggests the high venom/body mass 
ratio as one of the main causes for this,1 which implies that 
the dose of venom in children is relatively larger than adults, 
making them more susceptible to life-threatening swelling 
or neurotoxicity. In our study, children <10 years required 
antivenom more than any other age group. Furthermore, 
children appear to be at higher risk for allergic reactions and 
anaphylaxis from the antivenom, as confirmed by our results 
with the highest incidence (60%) of antivenom-associated 
complications occurring in children <11 years old. The reasons 
for this are unclear, but a contributory factor may be that the 
same dose is given to adults as children.
Antivenom administration is the cornerstone of treating 
severe life- or limb-threatening snakebites. The dose 
administered is related to the type of snakebite and the 
amount of venom injected, and not the weight of the patient. 
This means that the dose should not be reduced in children. 
Antivenom was administered to 22 patients (9%), the most 
common indication being RPS (47%). The mean time to 
Table I. Reactions to antivenom administration according to age group
    0 - 10 yrs (N=8)  11 - 20 yrs (N=7)  >20 yrs (N=7)
No adverse reaction       2 (25.0%)         4 (57.1%)      6 (85.7%)
Allergic reaction        3 (37.5%)         0       1 (14.3%)
Anaphylactic reaction       3 (37.5%)         3 (42.9%)      0
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antivenom administration from the time of the bite was 16 
hours. The initial dose used in this study was 40 ml polyvalent 
antivenom, with further doses required when patient response 
was inadequate (e.g. progression of swelling) and when no 
allergic or anaphylactic reactions were observed. Neurotoxic 
bites generally require higher doses of antivenom (up to 
100 ml). The ideal method of antivenom administration 
is not clearly established, but guidelines are set in the 
SAIMR package insert. The effectiveness of antihistamines, 
hydrocortisone and adrenaline in preventing anaphylaxis 
prior to antivenom administration has little evidence other 
than a theoretical basis. The risk of acute allergic reactions 
and anaphylaxis is not dose-related. Furthermore, the rate of 
antivenom administration over 10 minutes is recommended 
by the manufacturer, with no evidence that a slower rate of 
administration is safer.1,5
The relatively high risk of allergic and anaphylactic reactions 
to polyvalent antivenoms has led to recommendations that 
it be administered in a hospital setting and not ‘in the field’. 
Some First-World countries have developed more purified 
antivenoms such as the antivenin (Crotalidae) polyvalent 
(ACP) and the Crotalidae polyvalent immune fab (CroFab; 
FabAV) which are effective, with reduced adverse reactions.7,9 
The decision to use antivenom should not be taken lightly, 
and clinicians must weigh up risks versus benefits. An 
understanding of the characteristics of both the venom 
and the antivenom is paramount. Snake venom can cause 
reversible (e.g. coagulopathies, such as thrombocytopenia) 
and irreversible (e.g. severe swelling with necrosis and tissue 
death) injuries. Antivenom used timeously can prevent 
the progression of injuries from becoming severe or life-
threatening, and can be life-saving in cases of neurotoxicity 
in acute settings. On the other hand are the potential adverse 
effects of the antivenom. In all cases where antivenom is 
to be administered, the attending clinician should have 
full resuscitation equipment and drugs on hand to manage 
anaphylaxis.
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